Skip to main content
. 2023 Aug 28;11:e41833. doi: 10.2196/41833

Table 2.

Participant drug and alcohol use history data (N=154).

Characteristics Participants
Alcohol use disorder milestones, mean (SD)

Age of first drink 14.6 (2.9)

Age of regular drinking 19.5 (6.5)

Age at which drinking became problematic 27.9 (9.6)

Age of first quit attempt 31.6 (10.4)

Number of quit attempts 9.1 (31.1)
Lifetime history of treatment (can choose more than 1), n (%)

Long-term residential (>6 mo) 8 (5.2)

Short-term residential (<6 mo) 51 (33.1)

Outpatient 77 (50)

Individual counseling 100 (64.9)

Group counseling 65 (42.2)

Alcoholics anonymous or narcotics anonymous 96 (62.3)

Other 41 (26.6)
Received medication for alcohol use disorder, n (%)

Yes 62 (40.3)

No 92 (59.7)
DSM-5a alcohol use disorder symptom count, mean (SD) 8.9 (1.9)
Lifetime drug use, n (%)

Tobacco products (eg, cigarettes, chewing tobacco, and cigars) 122 (79.2)

Cannabis (eg, marijuana, pot, grass, and hash) 131 (85.1)

Cocaine (eg, coke and crack) 86 (55.8)

Amphetamine type stimulants (eg, speed, diet pills, and ecstasy) 81 (52.6)

Inhalants (eg, nitrous, glue, petrol, and paint thinner) 36 (23.4)

Sedatives or sleeping pills (eg, Valium, Serepax, and Rohypnol) 72 (46.8)

Hallucinogens (eg, LSDb, acid, mushrooms, PCPc, and Special K) 88 (57.1)

Opioids (eg, heroin, morphine, methadone, and codeine) 65 (42.2)
Current drug used, n (%)

Tobacco products (eg, cigarettes, chewing tobacco, and cigars) 84 (54.5)

Cannabis (eg, marijuana, pot, grass, and hash) 52 (33.8)

Cocaine (eg, coke and crack) 4 (2.6)

Amphetamine type stimulants (eg, speed, diet pills, and ecstasy) 11 (7.1)

Sedatives or sleeping pills (eg, Valium, Serepax, and Rohypnol) 24 (15.6)

Hallucinogens (eg, LSD, acid, mushrooms, PCP, and Special K) 9 (5.8)

Opioids (eg, heroin, morphine, methadone, and codeine) 9 (5.8)

aDSM-5: Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition.

bLSD: lysergic acid diethylamide.

cPCP: phencyclidine.

dCurrent refers to the previous month’s drug use reported at follow-up visits 1 or 2.